![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
November 25, 2024
EA5162 is testing a new therapy for certain patients with advanced NSCLC who have developed resistance to other treatments
September 17, 2024
This innovative real-world data study is developing an infrastructure to conduct a study comparing outcomes in patients with EGFR-mutated NSCLC receiving osimertinib with or without chemotherapy and not enrolled in a clinical trial
March 7, 2024
ACHIEVE is the first randomized phase 3 study to focus on older adults with advanced non-small cell lung cancer who are treated with pembrolizumab alone compared to those treated with pembrolizumab plus chemotherapy
March 7, 2024
This phase 3 randomized controlled trial is comparing first-line treatment with osimertinib plus bevacizumab versus osimertinib alone in patients with metastatic, EGFR-mutant non-small cell lung cancer
December 19, 2023
These four lung cancer treatment trials are all open and enrolling patients
December 22, 2021
This trial aims to help define the optimal first-line treatment for patients with advanced, EGFR-mutant NSCLC and elucidate mechanisms of resistance to therapy
May 28, 2021
Dr. Lovly is the recipient of the 2021 ECOG-ACRIN Young Investigator Award, a highly prestigious recognition of research excellence